Sobi-Innate Pharma Deal Turns Effective, Triggers $75M Payment
Stockholm – September 19, 2026 -- Swedish Orphan Biovitrum AB (Sobi) has paid Innate Pharma SA USD 75 million as their strategic oncology partnership becomes legally effective, following the expiration of antitrust waiting periods and satisfaction of other closing conditions.
Partnership clears regulatory hurdles first announced August 10, 2026
The deal, initially disclosed on August 10, 2026, grants Sobi exclusive global commercialisation rights to lacutamab pending accelerated approval, with an option to assume full global development rights if Phase 3 results are positive.